Tags: Novo Nordisk

Novo AS invests in Ophhtotech Corporation for the further development of drug Fovista. In an announcement made today, Ophthotech Corporation said it was able to raise US$175 million in funding to finance the global Phase 3 clinical program of its lead medication Fovista.